Ibogaine is a tryptamine. Because of the ibogaine molecule's tryptamine core, ibogaine acts as an agonist (binds to the receptor and triggers a response) for the 5-HT2A receptor. However what makes ibogaine's pharmacodynamic properties and subjective experience unique from that of other psychedelic tryptamines and serotonergic psychedelics is that it also acts as an antagonist (blocks agonists' effects) of the NMDA receptor set and an agonist for the κ-opioid receptor set.[
jak juz kalebx zamowisz i dajmy na to nie bedziesz mial co zrobic z reszta kapsulek to ja moge odkupic. Nie ma problemu.
The pharmacology of ibogaine is quite complex, affecting many different neurotransmitter systems simultaneously. Because of its fairly low potency at any of its target sites, ibogaine is used in doses anywhere from 5 mg/kg of body weight for a minor effect to 30 mg/kg in the cases of strong polysubstance addiction. It is unknown whether doses greater than 30 mg/kg in humans produce effects that are therapeutically beneficial, medically risky, or simply prolonged in duration. In animal neurotoxicity studies, there was no observable neurotoxicity of ibogaine at 25 mg/kg, but at 50 mg/kg, one-third of the rats had developed patches of neurodegeneration, and at doses of 75 mg/kg or above, all rats showed a characteristic pattern of degeneration of Purkinje neurons, mainly in the cerebellum
Użytkownicy przeglądający ten dział: Brak zidentyfikowanych użytkowników i 7 gości